• K Vendrell Rankin, Daniel L Jones, and Elain Benton.
• Baylor Tobacco Treatment Services, Department of Public Health Sciences, Baylor College of Dentistry TAMHSC, Dallas, Texas, USA.
• Tex Dent J. 2010 Jun 1;127(6):589-94.

AbstractTobacco companies continue to develop and aggressively market new products for oral use. Most new products are intended to dissolve in the mouth and swallow rather than spit out the juices. These products effectively circumvent smoke-free policies, decrease tobacco cessation efforts, and create individuals who use both smokeless tobacco (ST) and cigarettes. All ST products contain nicotine, carcinogens, and pose multiple health risks. The cancer and health risks associated with ST use extend well beyond the changes in the oral cavity and the risk of oral cancer. Unlike cigarettes, the contents of ST vary widely by brand and product posing difficulty in the use of the available pharmacotherapy for cessation. Although no uniform guidelines exist for the use of pharmacotherapy for smokeless tobacco cessation, research suggests that use of these drugs is effective. The most important motivator for quitting ST cessation remains in the hands of the dentist.

24 keywords...

hide…